Library Item - Page 36 of 792 Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

Evaluating long-term outcomes after low dose pegylated interferon-α combined with dasatinib in patients with chronic phase chronic myeloid leukemia

Evaluating long-term outcomes after low dose pegylated interferon-α combined with dasatinib in patients with chronic phase chronic myeloid leukemia

Posted by on Dec 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of low-dose pegylated (PEG) interferon-α (IFN-α) combined with dasatinib in patients with chronic-phase (CP) chronic myeloid leukemia (CML).  This study concluded that this treatment was safe and effective in the long-term in these...

Read More

Investigating the risk of thyroid disorders in survivors of Hodgkin lymphoma.

Investigating the risk of thyroid disorders in survivors of Hodgkin lymphoma.

Posted by on Dec 31, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the risk of developing a range of thyroid disorders in both childhood and adult-treated female survivors of Hodgkin lymphoma (HL). The data showed that the risk of developing thyroid disorders increased significantly over time in both childhood and adult-treated survivors of HL. Some background Hodgkin lymphoma...

Read More

Evaluating the effectiveness and safety of chemotherapy before surgery plus radiofrequency ablation for patients with colorectal cancer liver metastases.

Evaluating the effectiveness and safety of chemotherapy before surgery plus radiofrequency ablation for patients with colorectal cancer liver metastases.

Posted by on Dec 31, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) followed by radiofrequency ablation (RFA) for the treatment of patients with colorectal cancer liver metastasis. The data showed that NAC plus RFA improved survival outcomes in these patients. Some background Colorectal...

Read More

Comparing the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small cell lung cancer.

Comparing the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small cell lung cancer.

Posted by on Dec 31, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness of immune-based combination therapies as first-line treatment for advanced non-small-cell lung cancer (NSCLC). The data showed that immunotherapies plus chemotherapy combination was the best treatment for improving overall survival whereas, immunotherapy plus anti-angiogenic therapy plus chemotherapy...

Read More

Evaluating the risk of lung inflammation associated with immunotherapy in advanced melanoma.

Evaluating the risk of lung inflammation associated with immunotherapy in advanced melanoma.

Posted by on Dec 31, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the risk of pneumonitis (inflammation of the lung tissue) associated with immune checkpoint inhibitors (ICIs) for the treatment of patients with advanced melanoma. The data showed that ICIs were associated with a higher risk of pneumonitis compared with conventional chemotherapy in patients with advanced melanoma. Some...

Read More

Adding dalpiciclib to fulvestrant in patients with hormone receptor-positive and HER2-negative advanced breast cancer

Adding dalpiciclib to fulvestrant in patients with hormone receptor-positive and HER2-negative advanced breast cancer

Posted by on Dec 31, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of dalpiciclib (SHR6390) plus fulvestrant (Faslodex) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding dalpiciclib to fulvestrant was safe and significantly improved the survival without cancer worsening in...

Read More

Evaluating the safety and effectiveness of a four-in-one blood pressure pill early-on in patients with hypertension.

Evaluating the safety and effectiveness of a four-in-one blood pressure pill early-on in patients with hypertension.

Posted by on Dec 19, 2021 in Hypertension | 0 comments

In a nutshell This study investigated whether a single blood pressure (BP) pill containing 4 drugs (quadpill) at quarter doses is more effective than the standard dose of a single drug as initial treatment in patients with hypertension. The data showed that a quadpill was safe and more effective in getting BP under control than the standard...

Read More

Evaluating real-world outcomes of daratumumab in patients with multiple myeloma.

Evaluating real-world outcomes of daratumumab in patients with multiple myeloma.

Posted by on Dec 19, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness of daratumumab (Darzalex)-based therapy for patients with multiple myeloma (MM) in a real-world setting. The data showed that daratumumab-based therapy in a real-world setting was not as effective as in clinical trials. Some background Multiple myeloma (MM) is a type of cancer that comes from...

Read More

Evaluating the effectiveness and safety of immune checkpoint inhibitors in combination with radiotherapy in advanced melanoma.

Evaluating the effectiveness and safety of immune checkpoint inhibitors in combination with radiotherapy in advanced melanoma.

Posted by on Dec 19, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) in combination with palliative (treatment to relieve pain) radiotherapy (pRT) for the treatment of patients with advanced melanoma. The data showed that the addition of pRT to ICIs is effective and safe in these patients. Some background Melanoma is...

Read More

Comparing the effectiveness and safety of apalutamide with darolutamide for non-metastatic castration-resistant prostate cancer.

Comparing the effectiveness and safety of apalutamide with darolutamide for non-metastatic castration-resistant prostate cancer.

Posted by on Dec 19, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness and safety outcomes of androgen-deprivation therapy (ADT) with either apalutamide (Erleada) or darolutamide (Nubeqa) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC). The data showed that apalutamide plus ADT was safe and more effective in improving...

Read More

Can anti-diabetic drug use affect fracture risk in patients with type 2 diabetes?

Can anti-diabetic drug use affect fracture risk in patients with type 2 diabetes?

Posted by on Dec 19, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the safety of anti-diabetic drugs in the risk of fractures based on available data from clinical trials. The data showed differences in associations between the use of anti-diabetic drugs and fracture risk. Some background Patients with type 2 diabetes (T2D) are more prone to bone fragility (increased bone...

Read More

Lifestyle changes for patients with high blood pressure resistant to medications

Lifestyle changes for patients with high blood pressure resistant to medications

Posted by on Dec 19, 2021 in Hypertension | 0 comments

In a nutshell This study looked at the effects of diet and lifestyle changes for people with high blood pressure who did not respond to medication. It found that a four-month counseling program led to significant improvement in diet and exercise, blood pressure, and heart health. Some background Uncontrolled high blood pressure leads to cardiovascular...

Read More